Supernus Pharma (SUPN) Misses Q1 EPS by 58c, Beats on Revenue

Supernus Pharma (NASDAQ: SUPN) reported Q1 EPS of ($0.21), $0.58 worse than the analyst estimate of $0.37. Revenue for the quarter came in at $149.8 million versus the consensus estimate of $146.9 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Stay long AI-capex winners into the peak, Stifel says despite bubble fears
• Benchmark Reiterates Hold Rating on Old Dominion Freight Line (ODFL) as 'Quality Largely Priced in'
• Radoff-JEC Group pushes for board seats at Seer amid proxy fight